Clinical trial NCT06128343: Anatomical-Clinical Base of Adenocarcinoma Pancreatic
Official title: Anatomical-Clinical Base of Adenocarcinoma Pancreatic
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Adenocarcinoma
Carcinoma
Neoplasms
Keywords: Adenocarcinoma
fine-needle aspiration
endoscopic ultrasonography
epidemiology
biobank
DNA tumors
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
First posted: 2023-11-13
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 120
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with a pancreatic adenocarcinoma proven cytologically or histologically without any treatment

Brief summary: BACAP-2 is a prospective biobank dedicated to the pancreatic adenocarcinoma including clinical data and biological samples from tumor. The aim is to enrich the previous propective collection BACAP in order to support future research projects.

Detailed description: Pancreatic cancer represents the fourth cause of death by cancer in Western countries. In over 90% of cases, it is due to an adenocarcinoma. The only curative treatment for pancreatic cancer remains the surgical exeresis. This one can only be suggested as a curative treatment in only 10 to 15% of cases. Besides, prevention or screening is difficult to set up due to the absence of clearly identified risk factors or groups and to the absence of useful markers for the diagnosis in clinical practice.

The research efforts in this area must face a double challenge: saving time while improving the diagnosis period and strengthen the therapeutic equipment. It is important to identify and characterise the new molecular markers applicable for a better diagnosis and/or treatment (especially the response factors to chemotherapy).

The present project aims to enrich with fresh tumor tissue and somatic genetic analysis the existing propective collection BACAP in order to support support future research projects on:

* the development of new diagnostic tools,
* understanding the development of tumors of the pancreas
* the development of new therapeutic targets
* understanding the response to chemotherapy...

Eligibility criteria: Inclusion Criteria:

* Patient with pancreatic mass syndrome explored by ultrasound endoscopy with cytopuncture or
* Patient with pancreatic mass syndrome explored by an abdominal scanner with and without injection of product contrast and/or puncture of the mass or secondary lesions by radiological route or
* Patient with pancreatic adenocarcinoma proven histologically and/or cytologically

Exclusion Criteria:

* Patient with a pancreatic tumor whose analysis histological is not an adenocarcinoma
* Pregnant or breastfeeding patient

Primary outcomes:
measure: Enrichment of prospective BACAP collection
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: Haut-Lévêque Hospital
city: Béthune
country: France
facility: Béthune hospital center
city: Lille
country: France
facility: Huriez Hospital
city: Lyon
country: France
facility: Jean Mermoz private hosptila
city: Montpellier
country: France
facility: Saint Eloi Hospital
city: Montpellier
country: France
facility: Regional Cancer Center From Montpellier
city: Pau
country: France
facility: PAU hospital
city: Toulouse
country: France
facility: Rangueil hospital
Study officials:
affiliation: University Hospital, Toulouse
name: Barbara BOURNET, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: